Navigation Links
Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer
Date:6/3/2010

ma‚ and infectious disease. While Vice President of Clinical Research at CV Therapeutics‚ Dr. Hislop was the development leader for the company's first product, Ranexa® (ranolazine), and championed the NDA efforts for this cardiovascular compound. Prior to CVT‚ Dr. Hislop spent seven years at Proctor and Gamble as the worldwide clinical development manager for P&G's osteoporosis drug, Actonel® (risedronate sodium). He also worked at Eli Lilly and Company in the UK as a medical advisor for the endocrinology group. Dr. Hislop has a B.Sc. from University of Surrey in Medical Biochemistry and an M.D., B.S. from the University of London.

Dr. Pennington has over 25 years of experience in the pharmaceutical industry during which he was responsible for 14 NDA and BLA approvals in the United States and 10 product approvals in countries outside the US. He joined Anthera in 2007 from CoTherix, Inc. where he served as Executive Vice President and Chief Medical Officer of a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiovascular diseases. Previously, he was Executive Vice President, Medical and Scientific Affairs and Chief Medical Officer of InterMune, Inc., a publicly-traded biopharmaceutical company focused on the development, applied research and marketing of life-saving therapies for pulmonary and hepatic diseases, and also served as Vice President of Biological and Biotechnology Clinical Development of Bayer Corporation for 11 years. Prior to entering the pharmaceutical industry, Dr. Pennington also has years of experience in academia at Harvard Medical School and the University of California, San Francisco. He attended the University of Oregon School o
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
2. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
3. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
4. Anthera Presents Data on Varespladib at ATVB Meeting
5. Anthera Pharmaceuticals Forms Scientific Advisory Board
6. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
7. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
8. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
9. Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference
10. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
11. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015  Quest Diagnostics Incorporated ... diagnostic information services, announced that it is scheduled to ... New York.  Steve Rusckowski , the company,s President ... five point strategy.  The presentation is scheduled for Tuesday, ... The presentation will be webcast live during the ...
(Date:5/28/2015)... 27, 2015 Research and Markets( ... Jain PharmaBiotech,s new report "Nanobiotechnology Applications, ... An increasing use of nanobiotechnology ... anticipated. Nanotechnology will be applied at all ... for optimal delivery to diagnostic applications in ...
(Date:5/28/2015)... DUBLIN , May 27, 2015 ... addition of Jain PharmaBiotech,s new report "Cell ... their offering. This report describes and ... already started to play an important role in ... is replacing the old fashioned bone marrow transplants. ...
(Date:5/28/2015)... 28, 2015 The Academy of Model Aeronautics ... Day on August 15, 2015. National Model Aviation Day was ... to introduce model flying to the general public. , The ... to participate in the celebration by hosting events in their ... National Model Aviation Day events. View our online event ...
Breaking Biology Technology:Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2Model flying pilots celebrate the Academy of Model Aeronautics Foundation’s Third Annual National Model Aviation Day 2
... clinical trials of its treatment for ... inflammatory bowel disease., OKLAHOMA CITY, ... capital financing to fund clinical trials,testing the efficacy of its therapy ... the round and was joined by the,Oklahoma Seed Capital Fund and ...
... Sept. 18 The future of health care ... into practice and,health policy. But putting research into ... the pace of cutting-edge care. Kaiser,Permanente Colorado is ... at getting research into practice and policy more,quickly ...
... (Nasdaq: ONXX ) today announced that it ... on Monday, September 24, at 9:00,a.m. Eastern Time. ... the,presentation at: http://events.streamx.us/us/event/eventdetails.aspx?id=ubs20070924 It ... early in order to,register and download any necessary ...
Cached Biology Technology:Altheus Therapeutics Secures $3.6 Million in Venture Capital 2Kaiser Permanente Colorado Opens Center for Health Dissemination and Implementation Research 2
(Date:5/26/2015)... May 26, 2015 Research ... addition of the "Saudi Arabia Biometric Systems ... their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric ... is projected to grow at over 22% ... is attributed to the surging demand for better ...
(Date:5/21/2015)... May 21, 2015 According ... Market by Solutions (Hardware, Software, Services), by Applications (Surveillance ... others), by End-Users (Military & Defense & Commercial) ... Thermal Imaging Market is expected to grow from ... 2020, at a Compound Annual Growth Rate (CAGR) ...
(Date:5/19/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... similar to a drug used in the treatment of Parkinson's ... be used to develop drug therapy for cocaine abuse, new ... 23, 2005, issue of The Journal of Neuroscience, Jonathan Katz ... (NIDA) report the results of experiments showing that mice treated ...
... identified the proteins that allow specific brain cells to "change ... the cell. The findings, described in the March 24 issue ... day using it to protect cells that die in Lou ... what comes into the living room, these brain cells are ...
... identifies a critical inhibitory step that is a ... balance between neutrophil production and destruction. The research, ... that the process for disposal of dying neutrophils ... understanding of the processes that control neutrophil turnover ...
Cached Biology News:Potential Drug Target For Treating Cocaine Abuse Found 2Some Brain Cells 'Change Channels' To Fine-tune The Message 2Some Brain Cells 'Change Channels' To Fine-tune The Message 3White Blood Cell 'Waste Disposal' System Plays Critical Regulatory Role 2
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
... Assay, 96 wells. ELISA.Specific for total ... MMP-3. No cross-reactivity with MMP-1, -2, -9. ... use with cell culture supernatant, serum, plasma ... to -30 C. Category: Drug Screening ...
... Steady gravity-fed delivery of buffer and ... perfusion. Rat version. In Vivo Manual ... gravity-fed delivery of buffer and fixative ... to setup, use and clean--Complete system ...
Biology Products: